Abstracts tagged "corticosteroids"

Abstract Number: 712 • 2018 ACR/ARHP Annual Meeting
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Chiao-Feng Cheng, Cheng-Hsun Lu, Song-Chou Hsieh and Ko-Jen Li, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Tuberculosis (TB) has complex interplay with systemic lupus erythematosus (SLE). In addition, SLE, corticosteroid, and immunosuppressants are associated with TB infection. However, the prognostic…
Abstract Number: 1371 • 2018 ACR/ARHP Annual Meeting
Systemic Exposure of Triamcinolone Acetonide Following Bilateral Injection of Extended-Release Triamcinolone Acetonide and Standard Triamcinolone in Patients with Bilateral Knee Osteoarthritis
Alan J. Kivitz¹, Louis Kwong², Tammi Shlotzhauer³, Joelle Lufkin⁴, Teresa Curto⁵ and Scott Kelley⁴, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Department of Orthopaedic Surgery, Harbor-UCLA Medical Center, Torrance, CA, ³Rochester Clinical Research, Inc., Rochester, NY, ⁴Flexion Therapeutics, Inc., Burlington, MA, ⁵Cytel Inc., Waltham, MA
Background/Purpose: Current ACR guidelines recommend the use of IACS for short-term acute pain relief in patients (pts) with knee OA.1 Bilateral knee OA can occur…
Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Saba Ziaee¹, Siri Kunchakarra², Cara Joyce³, Mark Rabbat⁴ and Rochella A. Ostrowski⁵, ¹Loyola University Medical Center, Maywood, IL, ²Cardiology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Division of Cardiology, Loyola University Medical Center, Maywood, IL, ⁵Division of Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis. However, the incidence is >20% based on necropsy data. Given the poor yield…
Abstract Number: 1200 • 2017 ACR/ARHP Annual Meeting
Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo
Philip G. Conaghan¹, Francis Berenbaum², Virginia B. Kraus³, James Johnson⁴ and Scott Kelley⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Pierre & Marie Curie University, Saint-Antoine Hospital, Paris, France, ³Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, ⁴Summit Analytical, Denver, CO, ⁵Flexion Therapeutics, Inc., Burlington, MA
Background/Purpose: A recent meta-analysis concluded that intra-articular corticosteroids (IACS) for knee osteoarthritis (OA) may be associated with moderate improvement in pain compared with control treatment.1,2…
Abstract Number: 1313 • 2017 ACR/ARHP Annual Meeting
Oral Corticosteroid Use during Pregnancy and Risk of Preterm Birth in Women with Rheumatoid Arthritis
Kristin Palmsten¹, Gretchen Bandoli², Diana L Johnson¹, Ronghui Xu^3,4 and Christina D Chambers¹, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Pediatrics, University of California, San Diego, La Jolla, CA, ³Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴Department of Mathematics, University of California, San Diego, La Jolla, CA
Background/Purpose: There are limited data regarding gestational timing of oral corticosteroid (OCS) use during pregnancy and risk of preterm birth. The objective was to compare…
Abstract Number: 1442 • 2017 ACR/ARHP Annual Meeting
Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain Cantagrel⁵, Bernard Combe², Maxime Dougados⁶, René-Marc Flipo⁷, Alain Saraux⁸, Thierry Schaeverbeke⁹, Jean Sibilia¹⁰, Martin Soubrier¹¹, Olivier Vittecoq^12,13, Gabriel Baron¹⁴, Elodie Perrodeau¹⁵, Philippe Ravaud¹⁴ and Xavier Mariette¹⁶, ¹CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸Rheumatology, Brest University Hospital, Brest, France, ⁹Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹²INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ¹³Rheumatology Department and INSERM U 905, CHU Rouen, Rouen, France, ¹⁴Hôpital Hôtel Dieu, Paris, France, ¹⁵Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Little is known regarding the corticosteroid sparing effect of non-TNF biologics in rheumatoid arthritis (RA). Objectives : To compare the corticosteroid sparing effect of…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
Abstract Number: 2139 • 2017 ACR/ARHP Annual Meeting
Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: PM and DM are inflammatory myopathies, sometimes complicated by interstitial lung disease (ILD), myocarditis, arthritis, and malignancies. The intensity of immunosuppressive therapies depends on…
Abstract Number: 2319 • 2017 ACR/ARHP Annual Meeting
Bradycardia after High-Dose Solu-Medrol
Deirdre De Ranieri¹ and Umesh Dyamenahalli², ¹Pediatric Rheumatology, The University of Chicago Medicine, Chicago, IL, ²Pediatric Cardiology, University of Chicago, Chicago, IL
Background/Purpose: Methylprednisolone (MP) in both high dose (2mg/kg or higher) and pulse dose (30mg/kg up to 1000mg) is often used to treat patients with connective…
Abstract Number: 2394 • 2017 ACR/ARHP Annual Meeting
Differential Effect of Corticosteroids and Biological Dmards on Five-Year Radiographic Progression in Rheumatoid Arthritis: Results from a Weighted Cumulative Exposure Model Developed on the Espoir Cohort
Baptiste Louveau¹, Yann De Rycke¹, Alexandre Lafourcade¹, Alain Saraux², Francis Guillemin³, Florence Tubach⁴, Bruno Fautrel⁵ and David Hajage¹, ¹APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ²Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ³University of Lorraine, Nancy, France, Nancy, France, ⁴Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ⁵UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: In rheumatoid arthritis (RA), a strategic approach to achieve low-disease activity or remission is now recommended. Controlling joint damage is thus an important concern…
Abstract Number: 2604 • 2017 ACR/ARHP Annual Meeting
The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study
Ronald F van Vollenhoven¹, April Thompson², Bonnie Pobiner², Joe Eastman², Anne Hammer², James Groark³ and Damon Bass³, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²GSK Research Triangle Park, Research Triangle Park, NC, ³GSK Collegeville, Collegeville, PA
Background/Purpose: Reduced corticosteroid use is considered a key goal in SLE treatment. This concept of ‘steroid-sparing’, seen with intravenous (IV) belimumab based on cumulative steroid…
Abstract Number: 2906 • 2017 ACR/ARHP Annual Meeting
Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries
Dominick Sudano¹, C. Kent Kwoh², Lili Zhou³, Erin L. Ashbeck⁴ and Wei-Hsuan Lo-Ciganic⁵, ¹University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ⁴The University of Arizona Arthritis Center, Tucson, AZ, ⁵Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, Associate professor, TUCSON, AZ
Background/Purpose: Coccidioidomycosis (Cocci) is a fungal infection endemic to seven states in the US. Biologic response modifiers (BRMs) have been shown to increase the risk…
Abstract Number: 2956 • 2017 ACR/ARHP Annual Meeting
Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients from the Printo Trial
Gabriella Giancane¹, Claudio Lavarello¹, Angela Pistorio¹, Francesco Zulian¹, Bo Magnusson¹, Tadej Avcin¹, Fabrizia Corona¹, Valeria Gerloni², Serena Pastore¹, Roberto Marini¹, Silvana Martino¹, Anne Pagnier², Michel Rodiere¹, Christine Soler¹, Valda Stanevicha¹, Rebecca ten Cate³, Yosef Uziel¹, Jelena Vojinovic¹, Elena Fueri², Angelo Ravelli⁴, Alberto Martini⁵ and Nicolino Ruperto¹, ¹Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ²Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: At present no clear evidence based guidelines exist to standardize the tapering and discontinuation of corticosteroids (CS) in juvenile dermatomyositis (JDM). To provide evidence-based…
Abstract Number: 206 • 2017 ACR/ARHP Annual Meeting
Real World IGRA Testing in Rheumatology Practice
Paul DeMarco^1,2, Megan Bishop³, Ashling Smith⁴, Herbert S. B. Baraf^1,5, Andrew Gregory DeMarco⁶, Temitope Ademola⁷, Deborah Contreras⁸, Adalisa Enriquez RMA¹, Lisa Klein¹, Kayra Perez¹, Sandra Ventura¹, Janice Whyte-Whitworth¹, Vince Calhoun¹, Theresa Bass Goldman¹ and Alan K Matsumoto^1,9, ¹The Center for Rheumatology and Bone Research, Wheaton, MD, ²Division of Rheumatology, Department of Medicine, Georgetown University School of Medicine, Washington, DC, ³Clinical Trials, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁴2730 University Blvd West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Department of Medicine, George Washington University School of Medicine, Washington, DC, ⁶Department of Biochemistry and Molecular Cellular Biology, Georgetown University Department of Biochemistry and Molecular Cellular Biology, Washington, DC, ⁷The Center for Rheumatology and Bone Research, Washington, DC, ⁸2730 University Boulevard West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁹Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Mycobacterium tuberculosis (MTb) screening is routine for clinical trial protocols, & authorization for immunomodulators use by health insurances. Real world data is needed to…
Abstract Number: 787 • 2017 ACR/ARHP Annual Meeting
Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis
Alexandra Addario¹, Quitterie Reynaud^2,3, Maxime Samson⁴, Mathilde Francois³, Stéphane Durupt³, Francois Gueyffier¹, Michel Cucherat¹, Isabelle Durieu^2,5 and Jean-Christophe Lega^3,6, ¹Equipe Evaluation et Modélisation des Effets thérapeutiques, Lyon 1 University, Lyon, France, ²HESPER group, Lyon 1 University, Lyon, France, ³Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁴Department of Internal Medicine and Clinical Immunolgy, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Department of Internal and Vascular, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁶Equipe Evaluation et Modélisation des Effets thérapeutiques, UMR CNR 5558, Lyon 1 University, Lyon, France
Background/Purpose: The relapse rate of giant cell arteritis (GCA) in the patients treated by corticosteroids (CS) varied widely in observational series and randomized trials. The…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].